| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diethylstilbestrol | 92 | 2018 | 119 | 7.160 |
Why?
|
| Prenatal Exposure Delayed Effects | 45 | 2018 | 153 | 4.880 |
Why?
|
| Vaginal Neoplasms | 58 | 2018 | 83 | 4.030 |
Why?
|
| Uterine Cervical Neoplasms | 50 | 2018 | 275 | 2.950 |
Why?
|
| Estrogens, Non-Steroidal | 26 | 2015 | 30 | 2.590 |
Why?
|
| Adenocarcinoma, Clear Cell | 10 | 2018 | 62 | 2.280 |
Why?
|
| Pregnancy | 95 | 2018 | 2901 | 1.280 |
Why?
|
| Adenocarcinoma | 53 | 2015 | 1169 | 1.240 |
Why?
|
| Vaginal Smears | 13 | 2016 | 68 | 0.780 |
Why?
|
| Carcinogens | 8 | 2006 | 108 | 0.740 |
Why?
|
| Abnormalities, Drug-Induced | 7 | 2015 | 20 | 0.660 |
Why?
|
| Female | 148 | 2018 | 44566 | 0.570 |
Why?
|
| Ovarian Neoplasms | 14 | 2005 | 744 | 0.570 |
Why?
|
| Genital Neoplasms, Female | 9 | 2015 | 107 | 0.560 |
Why?
|
| Abortion, Spontaneous | 5 | 2015 | 66 | 0.540 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 232 | 0.470 |
Why?
|
| Follow-Up Studies | 30 | 2018 | 3639 | 0.470 |
Why?
|
| Adult | 86 | 2018 | 25648 | 0.430 |
Why?
|
| Humans | 151 | 2018 | 86656 | 0.410 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2016 | 27 | 0.400 |
Why?
|
| Maternal-Fetal Exchange | 23 | 2018 | 76 | 0.380 |
Why?
|
| Adolescent | 46 | 2018 | 8988 | 0.350 |
Why?
|
| Cervix Uteri | 15 | 2016 | 65 | 0.350 |
Why?
|
| Vaginal Diseases | 16 | 1984 | 27 | 0.340 |
Why?
|
| Twins | 2 | 2008 | 65 | 0.340 |
Why?
|
| Breast Neoplasms | 13 | 2011 | 2904 | 0.340 |
Why?
|
| Fetal Blood | 2 | 2001 | 90 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2016 | 1077 | 0.330 |
Why?
|
| Delivery, Obstetric | 1 | 2008 | 113 | 0.320 |
Why?
|
| United States | 35 | 2018 | 6674 | 0.310 |
Why?
|
| Papillomaviridae | 2 | 2001 | 153 | 0.300 |
Why?
|
| Menstruation Disturbances | 3 | 2018 | 24 | 0.270 |
Why?
|
| Fetus | 12 | 1981 | 226 | 0.260 |
Why?
|
| Risk | 19 | 2018 | 674 | 0.260 |
Why?
|
| Cohort Studies | 14 | 2017 | 2765 | 0.250 |
Why?
|
| Urogenital Abnormalities | 3 | 2015 | 19 | 0.250 |
Why?
|
| Papanicolaou Test | 3 | 2016 | 38 | 0.240 |
Why?
|
| Endocrine Disruptors | 2 | 2018 | 27 | 0.240 |
Why?
|
| Registries | 11 | 2014 | 703 | 0.230 |
Why?
|
| Vagina | 17 | 2000 | 161 | 0.230 |
Why?
|
| Incidence | 9 | 2017 | 1578 | 0.230 |
Why?
|
| Obstetrics | 2 | 1999 | 120 | 0.230 |
Why?
|
| Fertility | 2 | 1995 | 115 | 0.220 |
Why?
|
| Odds Ratio | 8 | 2009 | 679 | 0.220 |
Why?
|
| Maternal Exposure | 3 | 2009 | 57 | 0.220 |
Why?
|
| Age Factors | 19 | 2016 | 1849 | 0.210 |
Why?
|
| Middle Aged | 28 | 2018 | 25027 | 0.210 |
Why?
|
| Risk Factors | 18 | 2015 | 5416 | 0.210 |
Why?
|
| Apgar Score | 1 | 2001 | 13 | 0.200 |
Why?
|
| Lead Radioisotopes | 3 | 1989 | 6 | 0.200 |
Why?
|
| Menopause | 3 | 2006 | 71 | 0.200 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2001 | 39 | 0.200 |
Why?
|
| Child | 24 | 2017 | 6933 | 0.200 |
Why?
|
| S100 Proteins | 1 | 2001 | 50 | 0.190 |
Why?
|
| Time Factors | 15 | 2017 | 5215 | 0.190 |
Why?
|
| Gestational Age | 11 | 2009 | 312 | 0.190 |
Why?
|
| Infant, Newborn | 9 | 2008 | 2380 | 0.180 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2000 | 40 | 0.180 |
Why?
|
| Uterine Neoplasms | 5 | 2005 | 227 | 0.180 |
Why?
|
| Young Adult | 5 | 2018 | 5977 | 0.180 |
Why?
|
| Pregnancy Complications | 10 | 2011 | 337 | 0.170 |
Why?
|
| Infertility, Female | 5 | 2006 | 93 | 0.160 |
Why?
|
| Parity | 5 | 2008 | 93 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2018 | 1540 | 0.150 |
Why?
|
| Menarche | 2 | 1995 | 24 | 0.150 |
Why?
|
| Gynecology | 1 | 1999 | 124 | 0.150 |
Why?
|
| Brain | 3 | 2001 | 2220 | 0.150 |
Why?
|
| Premature Birth | 1 | 2018 | 113 | 0.150 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 1994 | 122 | 0.150 |
Why?
|
| Receptors, Estrogen | 5 | 1989 | 384 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 1997 | 48 | 0.150 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 827 | 0.140 |
Why?
|
| Menstrual Cycle | 3 | 1994 | 55 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 141 | 0.140 |
Why?
|
| Uterine Cervical Diseases | 5 | 1983 | 8 | 0.130 |
Why?
|
| Birth Weight | 3 | 2006 | 145 | 0.130 |
Why?
|
| Obstetric Labor Complications | 1 | 1995 | 34 | 0.130 |
Why?
|
| Terminology as Topic | 3 | 1992 | 217 | 0.130 |
Why?
|
| Mass Screening | 4 | 2015 | 619 | 0.130 |
Why?
|
| Bacterial Infections | 3 | 2001 | 183 | 0.130 |
Why?
|
| Surveys and Questionnaires | 11 | 2015 | 2502 | 0.130 |
Why?
|
| Fever | 1 | 1995 | 125 | 0.130 |
Why?
|
| Mothers | 2 | 2018 | 141 | 0.130 |
Why?
|
| Hypersensitivity | 1 | 1996 | 154 | 0.120 |
Why?
|
| Tumor Virus Infections | 1 | 1994 | 81 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 1996 | 241 | 0.120 |
Why?
|
| Pregnancy Outcome | 2 | 2008 | 247 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 1989 | 2438 | 0.110 |
Why?
|
| Cytodiagnosis | 4 | 1982 | 42 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 1989 | 1313 | 0.110 |
Why?
|
| Medical Records | 2 | 2008 | 119 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2014 | 176 | 0.110 |
Why?
|
| Biopsy, Needle | 3 | 1989 | 234 | 0.110 |
Why?
|
| Uterus | 5 | 2007 | 215 | 0.110 |
Why?
|
| Maternal Age | 3 | 2008 | 44 | 0.110 |
Why?
|
| Intelligence | 1 | 1992 | 71 | 0.110 |
Why?
|
| Contraception | 1 | 1993 | 88 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 1996 | 864 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1994 | 381 | 0.100 |
Why?
|
| Proportional Hazards Models | 6 | 2013 | 860 | 0.100 |
Why?
|
| Combined Modality Therapy | 6 | 2014 | 1686 | 0.100 |
Why?
|
| Physical Examination | 2 | 2008 | 149 | 0.100 |
Why?
|
| History, 20th Century | 3 | 1999 | 312 | 0.100 |
Why?
|
| Precancerous Conditions | 5 | 1994 | 196 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2013 | 121 | 0.100 |
Why?
|
| Surgical Wound Infection | 2 | 1993 | 182 | 0.100 |
Why?
|
| Motor Activity | 1 | 2014 | 327 | 0.100 |
Why?
|
| Aged | 11 | 2017 | 18407 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 1994 | 239 | 0.100 |
Why?
|
| Pathology, Clinical | 1 | 1991 | 33 | 0.100 |
Why?
|
| Breast Diseases | 2 | 1989 | 97 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 1993 | 28 | 0.100 |
Why?
|
| Prognosis | 6 | 2001 | 3681 | 0.100 |
Why?
|
| Sweden | 2 | 2008 | 40 | 0.100 |
Why?
|
| DNA, Neoplasm | 2 | 1983 | 265 | 0.090 |
Why?
|
| Infant Mortality | 2 | 2008 | 59 | 0.090 |
Why?
|
| Insurance, Liability | 1 | 1990 | 10 | 0.090 |
Why?
|
| Vulva | 1 | 1990 | 23 | 0.090 |
Why?
|
| Male | 22 | 2014 | 40995 | 0.090 |
Why?
|
| Bismuth | 1 | 1989 | 8 | 0.090 |
Why?
|
| Vulvar Neoplasms | 1 | 1990 | 20 | 0.090 |
Why?
|
| Infant, Premature | 3 | 2008 | 290 | 0.090 |
Why?
|
| Doxorubicin | 4 | 1989 | 295 | 0.090 |
Why?
|
| Radioisotopes | 1 | 1989 | 45 | 0.090 |
Why?
|
| Pelvic Exenteration | 1 | 1989 | 5 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2015 | 1809 | 0.090 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2001 | 111 | 0.090 |
Why?
|
| Cefuroxime | 1 | 1989 | 3 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 2261 | 0.090 |
Why?
|
| Malpractice | 1 | 1990 | 57 | 0.090 |
Why?
|
| Premedication | 1 | 1989 | 54 | 0.090 |
Why?
|
| Smoking | 3 | 1992 | 609 | 0.090 |
Why?
|
| Cephalosporins | 1 | 1989 | 24 | 0.090 |
Why?
|
| Publishing | 1 | 1990 | 90 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 4 | 1990 | 1380 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1990 | 176 | 0.090 |
Why?
|
| Mental Recall | 1 | 1990 | 159 | 0.090 |
Why?
|
| Neoplasms | 5 | 2008 | 2898 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1994 | 1197 | 0.080 |
Why?
|
| Genital Diseases, Female | 3 | 1981 | 24 | 0.080 |
Why?
|
| Breech Presentation | 1 | 2008 | 12 | 0.080 |
Why?
|
| Leg | 1 | 1989 | 137 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 1990 | 177 | 0.080 |
Why?
|
| Term Birth | 1 | 2008 | 8 | 0.080 |
Why?
|
| Reproduction | 2 | 2018 | 195 | 0.080 |
Why?
|
| Aortic Aneurysm | 1 | 1989 | 80 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 1989 | 134 | 0.080 |
Why?
|
| Neoplasm Staging | 5 | 2000 | 1938 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1989 | 107 | 0.080 |
Why?
|
| Contraceptives, Oral | 4 | 2001 | 46 | 0.080 |
Why?
|
| Mammography | 1 | 2011 | 463 | 0.080 |
Why?
|
| Estradiol Congeners | 2 | 2006 | 8 | 0.080 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 1988 | 9 | 0.080 |
Why?
|
| Behavior | 1 | 2008 | 85 | 0.080 |
Why?
|
| Sex Ratio | 1 | 2007 | 22 | 0.080 |
Why?
|
| Serpins | 1 | 1987 | 29 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 2 | 1992 | 50 | 0.080 |
Why?
|
| Cesarean Section | 1 | 2008 | 137 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1989 | 228 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2001 | 105 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2000 | 18 | 0.070 |
Why?
|
| Mortality | 2 | 2006 | 150 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 1993 | 747 | 0.070 |
Why?
|
| Puberty | 1 | 2007 | 59 | 0.070 |
Why?
|
| Neoplasm Metastasis | 8 | 1988 | 1056 | 0.070 |
Why?
|
| Colposcopy | 3 | 2001 | 14 | 0.070 |
Why?
|
| Epithelium | 9 | 1988 | 319 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2007 | 180 | 0.070 |
Why?
|
| Logistic Models | 3 | 2015 | 1185 | 0.070 |
Why?
|
| Carcinoma | 1 | 1989 | 436 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 1990 | 533 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 1996 | 1824 | 0.070 |
Why?
|
| Hysterectomy | 4 | 1993 | 146 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 1994 | 1464 | 0.070 |
Why?
|
| Hypospadias | 1 | 2005 | 5 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 1987 | 325 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 805 | 0.070 |
Why?
|
| Urogenital Neoplasms | 2 | 2008 | 23 | 0.060 |
Why?
|
| Cisplatin | 4 | 1989 | 612 | 0.060 |
Why?
|
| Agranulocytosis | 1 | 1984 | 20 | 0.060 |
Why?
|
| Fetal Death | 2 | 2001 | 56 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1374 | 0.060 |
Why?
|
| Lithium | 1 | 1984 | 59 | 0.060 |
Why?
|
| Pre-Eclampsia | 1 | 2007 | 246 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 2001 | 229 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2014 | 4212 | 0.060 |
Why?
|
| Nuclear Family | 3 | 2009 | 92 | 0.060 |
Why?
|
| Neutropenia | 1 | 1984 | 215 | 0.060 |
Why?
|
| Brachytherapy | 2 | 1999 | 119 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 1984 | 183 | 0.060 |
Why?
|
| Endometrial Hyperplasia | 1 | 1982 | 8 | 0.060 |
Why?
|
| Genitalia, Male | 3 | 1995 | 24 | 0.050 |
Why?
|
| Urethral Diseases | 1 | 1982 | 15 | 0.050 |
Why?
|
| Electrosurgery | 1 | 2001 | 9 | 0.050 |
Why?
|
| Genitalia, Female | 1 | 1981 | 25 | 0.050 |
Why?
|
| Cyclophosphamide | 3 | 1989 | 299 | 0.050 |
Why?
|
| Peroxidases | 1 | 1981 | 34 | 0.050 |
Why?
|
| Chorioamnionitis | 1 | 2001 | 15 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 568 | 0.050 |
Why?
|
| Germany | 2 | 2014 | 72 | 0.050 |
Why?
|
| Triage | 1 | 2001 | 108 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 1990 | 274 | 0.050 |
Why?
|
| Sex Factors | 3 | 2014 | 1053 | 0.050 |
Why?
|
| Amniotic Fluid | 2 | 1979 | 30 | 0.050 |
Why?
|
| Retrospective Studies | 8 | 2008 | 8476 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1999 | 1960 | 0.050 |
Why?
|
| Causality | 1 | 2000 | 81 | 0.050 |
Why?
|
| Coitus | 1 | 1979 | 20 | 0.050 |
Why?
|
| Fetal Diseases | 1 | 1979 | 82 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2007 | 596 | 0.040 |
Why?
|
| Triazenes | 1 | 1979 | 1 | 0.040 |
Why?
|
| Carcinoma in Situ | 3 | 1994 | 53 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2000 | 77 | 0.040 |
Why?
|
| Vincristine | 1 | 1979 | 111 | 0.040 |
Why?
|
| Probability | 2 | 2001 | 354 | 0.040 |
Why?
|
| Menstruation | 4 | 1981 | 30 | 0.040 |
Why?
|
| Uterine Hemorrhage | 2 | 1976 | 19 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 70 | 0.040 |
Why?
|
| Cell Line | 3 | 1989 | 2476 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 1979 | 40 | 0.040 |
Why?
|
| Dacarbazine | 1 | 1979 | 102 | 0.040 |
Why?
|
| Physicians, Women | 1 | 1999 | 53 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2008 | 3612 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2001 | 692 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 6511 | 0.040 |
Why?
|
| Terminal Care | 1 | 1999 | 130 | 0.040 |
Why?
|
| Metaplasia | 4 | 1979 | 37 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 267 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2000 | 193 | 0.040 |
Why?
|
| Endometrium | 2 | 1989 | 48 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1991 | 0.040 |
Why?
|
| Progesterone | 2 | 1974 | 110 | 0.040 |
Why?
|
| Sex Chromatin | 1 | 1976 | 4 | 0.040 |
Why?
|
| Sex Determination Analysis | 1 | 1976 | 18 | 0.040 |
Why?
|
| Remission Induction | 2 | 2007 | 722 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 493 | 0.030 |
Why?
|
| Estrogens | 2 | 1974 | 200 | 0.030 |
Why?
|
| Lymphatic Metastasis | 4 | 1989 | 486 | 0.030 |
Why?
|
| Analgesia, Epidural | 1 | 1995 | 38 | 0.030 |
Why?
|
| Altretamine | 2 | 1986 | 4 | 0.030 |
Why?
|
| Infertility, Male | 1 | 1995 | 24 | 0.030 |
Why?
|
| Sweating | 1 | 1995 | 1 | 0.030 |
Why?
|
| Climacteric | 1 | 1995 | 4 | 0.030 |
Why?
|
| Societies, Medical | 1 | 1999 | 573 | 0.030 |
Why?
|
| Reoperation | 2 | 1989 | 593 | 0.030 |
Why?
|
| Radiation Effects | 1 | 1974 | 28 | 0.030 |
Why?
|
| Cell Nucleus | 4 | 1983 | 581 | 0.030 |
Why?
|
| Propylthiouracil | 2 | 1965 | 24 | 0.030 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 1995 | 20 | 0.030 |
Why?
|
| Testosterone | 3 | 1992 | 271 | 0.030 |
Why?
|
| Austria | 1 | 2014 | 19 | 0.030 |
Why?
|
| Hyperthyroidism | 2 | 1965 | 75 | 0.030 |
Why?
|
| Age of Onset | 1 | 1995 | 310 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1994 | 81 | 0.030 |
Why?
|
| Disorders of Sex Development | 1 | 1973 | 18 | 0.030 |
Why?
|
| Cleft Palate | 1 | 1973 | 26 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1994 | 265 | 0.030 |
Why?
|
| Prevalence | 2 | 1994 | 1240 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2015 | 220 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 1976 | 238 | 0.030 |
Why?
|
| Hormones | 1 | 1973 | 141 | 0.030 |
Why?
|
| Abdomen | 1 | 1993 | 120 | 0.030 |
Why?
|
| Family | 1 | 1994 | 311 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1992 | 147 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 1994 | 169 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 219 | 0.030 |
Why?
|
| Aptitude | 1 | 1992 | 10 | 0.030 |
Why?
|
| Luteinizing Hormone | 2 | 1992 | 167 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 567 | 0.030 |
Why?
|
| DNA Probes, HPV | 1 | 1992 | 3 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 1995 | 302 | 0.030 |
Why?
|
| Male Urogenital Diseases | 1 | 1992 | 9 | 0.030 |
Why?
|
| Female Urogenital Diseases | 1 | 1992 | 9 | 0.030 |
Why?
|
| Semen | 1 | 1992 | 13 | 0.030 |
Why?
|
| Menopause, Premature | 1 | 2011 | 3 | 0.030 |
Why?
|
| Stillbirth | 1 | 2011 | 9 | 0.030 |
Why?
|
| Testicular Neoplasms | 2 | 2001 | 105 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1992 | 153 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 1989 | 303 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 378 | 0.020 |
Why?
|
| Educational Status | 2 | 2006 | 190 | 0.020 |
Why?
|
| Alpha Particles | 1 | 1990 | 4 | 0.020 |
Why?
|
| Beta Particles | 1 | 1990 | 5 | 0.020 |
Why?
|
| Uterine Cervical Erosion | 3 | 1975 | 3 | 0.020 |
Why?
|
| Mesonephroma | 1 | 1970 | 5 | 0.020 |
Why?
|
| Health Behavior | 1 | 2011 | 183 | 0.020 |
Why?
|
| Radioisotope Teletherapy | 1 | 1989 | 4 | 0.020 |
Why?
|
| Pregnancy, Ectopic | 2 | 2000 | 36 | 0.020 |
Why?
|
| Energy Transfer | 1 | 1989 | 25 | 0.020 |
Why?
|
| Biopsy | 5 | 1983 | 1163 | 0.020 |
Why?
|
| Endometriosis | 1 | 1970 | 58 | 0.020 |
Why?
|
| Nipples | 1 | 1989 | 37 | 0.020 |
Why?
|
| Cryptorchidism | 1 | 2009 | 11 | 0.020 |
Why?
|
| Internship and Residency | 1 | 1999 | 1010 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 1990 | 225 | 0.020 |
Why?
|
| Vinblastine | 1 | 1989 | 108 | 0.020 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 1989 | 7 | 0.020 |
Why?
|
| Bioprosthesis | 1 | 1989 | 36 | 0.020 |
Why?
|
| Saphenous Vein | 1 | 1989 | 61 | 0.020 |
Why?
|
| Bleomycin | 1 | 1989 | 98 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1989 | 102 | 0.020 |
Why?
|
| Etoposide | 1 | 1989 | 196 | 0.020 |
Why?
|
| Myometrium | 1 | 1989 | 46 | 0.020 |
Why?
|
| Histocytochemistry | 3 | 1985 | 130 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1990 | 156 | 0.020 |
Why?
|
| Administration, Intravaginal | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hysterosalpingography | 1 | 1988 | 7 | 0.020 |
Why?
|
| Carrier Proteins | 3 | 1989 | 675 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1989 | 1041 | 0.020 |
Why?
|
| Steroids | 1 | 1989 | 176 | 0.020 |
Why?
|
| Cognition | 1 | 1992 | 571 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1987 | 11 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1987 | 41 | 0.020 |
Why?
|
| Radiography | 1 | 1989 | 808 | 0.020 |
Why?
|
| Ischemia | 1 | 1989 | 243 | 0.020 |
Why?
|
| Preoperative Care | 1 | 1990 | 397 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 1987 | 12 | 0.020 |
Why?
|
| Cell Survival | 1 | 1989 | 971 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 224 | 0.020 |
Why?
|
| Epilepsies, Myoclonic | 1 | 1967 | 13 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 228 | 0.020 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1986 | 49 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 239 | 0.020 |
Why?
|
| Massachusetts | 1 | 1986 | 33 | 0.020 |
Why?
|
| Cytosol | 2 | 1989 | 190 | 0.020 |
Why?
|
| Cytoplasm | 3 | 1976 | 282 | 0.020 |
Why?
|
| Fluorouracil | 1 | 1988 | 556 | 0.020 |
Why?
|
| United Kingdom | 1 | 2006 | 164 | 0.020 |
Why?
|
| Leukemia | 1 | 2008 | 320 | 0.020 |
Why?
|
| Melphalan | 1 | 1986 | 98 | 0.020 |
Why?
|
| Bacteria | 1 | 1989 | 449 | 0.020 |
Why?
|
| Animals | 6 | 1989 | 26706 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1988 | 453 | 0.020 |
Why?
|
| Ovarian Cysts | 1 | 2005 | 17 | 0.020 |
Why?
|
| Cause of Death | 1 | 2006 | 277 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1986 | 238 | 0.020 |
Why?
|
| Seasons | 1 | 1986 | 223 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1984 | 14 | 0.020 |
Why?
|
| Lithium Carbonate | 1 | 1984 | 8 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1990 | 584 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 1965 | 270 | 0.010 |
Why?
|
| Antithyroid Agents | 1 | 1963 | 20 | 0.010 |
Why?
|
| Polyploidy | 1 | 1983 | 17 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1965 | 321 | 0.010 |
Why?
|
| Reproductive History | 1 | 2002 | 8 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 1019 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1967 | 709 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 610 | 0.010 |
Why?
|
| Prolapse | 1 | 1982 | 10 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2006 | 481 | 0.010 |
Why?
|
| Stem Cells | 1 | 1984 | 358 | 0.010 |
Why?
|
| Spermatozoa | 1 | 1981 | 62 | 0.010 |
Why?
|
| Hyperplasia | 2 | 1979 | 148 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2001 | 91 | 0.010 |
Why?
|
| Pelvic Neoplasms | 2 | 1979 | 45 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 1 | 2001 | 35 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 2001 | 18 | 0.010 |
Why?
|
| History, 16th Century | 1 | 2001 | 9 | 0.010 |
Why?
|
| History, 17th Century | 1 | 2001 | 12 | 0.010 |
Why?
|
| Leiomyoma | 1 | 2005 | 191 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1983 | 503 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2001 | 45 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 177 | 0.010 |
Why?
|
| Rabbits | 1 | 1981 | 638 | 0.010 |
Why?
|
| Obstetric Labor, Premature | 1 | 2000 | 58 | 0.010 |
Why?
|
| Pregnancy, Multiple | 1 | 1980 | 37 | 0.010 |
Why?
|
| Fetal Distress | 1 | 1979 | 7 | 0.010 |
Why?
|
| Reference Values | 1 | 2001 | 673 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1979 | 59 | 0.010 |
Why?
|
| Adenoma | 1 | 1981 | 237 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1979 | 53 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1978 | 66 | 0.010 |
Why?
|
| Pregnancy Trimester, First | 1 | 1978 | 63 | 0.010 |
Why?
|
| Mosaicism | 1 | 1978 | 67 | 0.010 |
Why?
|
| Mice | 2 | 1989 | 11439 | 0.010 |
Why?
|
| Placenta | 1 | 1979 | 176 | 0.010 |
Why?
|
| Neutrophils | 1 | 1979 | 308 | 0.010 |
Why?
|
| DNA | 1 | 1983 | 1295 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1999 | 292 | 0.010 |
Why?
|
| Research Design | 2 | 1978 | 594 | 0.010 |
Why?
|
| Comorbidity | 1 | 2001 | 945 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1983 | 1564 | 0.010 |
Why?
|
| Aging | 1 | 1981 | 693 | 0.010 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 1976 | 3 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1979 | 895 | 0.010 |
Why?
|
| Haplorhini | 1 | 1976 | 82 | 0.010 |
Why?
|
| Angiography | 1 | 1976 | 206 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1975 | 83 | 0.010 |
Why?
|
| Social Class | 1 | 1975 | 128 | 0.010 |
Why?
|
| Suppositories | 1 | 1974 | 3 | 0.010 |
Why?
|
| X-Rays | 1 | 1974 | 130 | 0.010 |
Why?
|
| Ethisterone | 1 | 1973 | 1 | 0.010 |
Why?
|
| Methandrostenolone | 1 | 1973 | 1 | 0.010 |
Why?
|
| Methyltestosterone | 1 | 1973 | 1 | 0.010 |
Why?
|
| Mestranol | 1 | 1973 | 4 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 1973 | 6 | 0.010 |
Why?
|
| Tinidazole | 1 | 1993 | 1 | 0.010 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 1973 | 16 | 0.010 |
Why?
|
| Norethindrone | 1 | 1973 | 12 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 1973 | 16 | 0.010 |
Why?
|
| Cefazolin | 1 | 1993 | 7 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1974 | 97 | 0.010 |
Why?
|
| Ovarian Diseases | 1 | 1973 | 32 | 0.010 |
Why?
|
| Metronidazole | 1 | 1993 | 26 | 0.010 |
Why?
|
| Glycogen | 1 | 1974 | 59 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1976 | 460 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1974 | 165 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1973 | 131 | 0.010 |
Why?
|
| Chicago | 1 | 1978 | 1380 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1973 | 264 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1973 | 261 | 0.010 |
Why?
|
| Parents | 1 | 1975 | 272 | 0.010 |
Why?
|
| New York | 1 | 1971 | 69 | 0.010 |
Why?
|
| Abortion, Threatened | 1 | 1971 | 1 | 0.010 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 1973 | 203 | 0.010 |
Why?
|
| Europe | 1 | 1971 | 309 | 0.010 |
Why?
|
| Rats | 2 | 1989 | 4004 | 0.010 |
Why?
|
| Breast Feeding | 1 | 1971 | 91 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1974 | 670 | 0.010 |
Why?
|
| Charcoal | 1 | 1989 | 13 | 0.010 |
Why?
|
| Dextrans | 1 | 1989 | 77 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 1979 | 2262 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1989 | 312 | 0.010 |
Why?
|
| Epilepsy, Absence | 1 | 1967 | 8 | 0.000 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 1967 | 8 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1989 | 1059 | 0.000 |
Why?
|
| Electromyography | 1 | 1967 | 184 | 0.000 |
Why?
|
| Scintillation Counting | 1 | 1985 | 5 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1985 | 112 | 0.000 |
Why?
|
| Methods | 1 | 1985 | 152 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1985 | 103 | 0.000 |
Why?
|
| Evoked Potentials | 1 | 1967 | 190 | 0.000 |
Why?
|
| Spinal Cord | 1 | 1967 | 248 | 0.000 |
Why?
|
| Ovulation | 1 | 1984 | 68 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 504 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1967 | 311 | 0.000 |
Why?
|
| Pedigree | 1 | 1967 | 966 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1965 | 170 | 0.000 |
Why?
|
| Tamoxifen | 1 | 1985 | 168 | 0.000 |
Why?
|
| Photometry | 1 | 1983 | 14 | 0.000 |
Why?
|
| Data Display | 1 | 1983 | 24 | 0.000 |
Why?
|
| Ploidies | 1 | 1983 | 40 | 0.000 |
Why?
|
| Computers | 1 | 1983 | 112 | 0.000 |
Why?
|
| Quality Control | 1 | 1983 | 117 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1985 | 457 | 0.000 |
Why?
|
| Ectoderm | 1 | 1982 | 29 | 0.000 |
Why?
|
| Phenotype | 1 | 1967 | 2389 | 0.000 |
Why?
|
| Cell Nucleolus | 1 | 1974 | 23 | 0.000 |
Why?
|
| Ascitic Fluid | 1 | 1974 | 37 | 0.000 |
Why?
|
| 17-Hydroxycorticosteroids | 1 | 1973 | 6 | 0.000 |
Why?
|
| 17-Ketosteroids | 1 | 1973 | 13 | 0.000 |
Why?
|
| Androstenedione | 1 | 1973 | 29 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1973 | 121 | 0.000 |
Why?
|
| Hirsutism | 1 | 1973 | 61 | 0.000 |
Why?
|
| Diabetes Complications | 1 | 1973 | 207 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1973 | 326 | 0.000 |
Why?
|